Cargando…

Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases

BACKGROUND: It is now recognized that many anticancer treatments positively modulate the antitumor immune response. Clinical and experimental studies have shown that inhibitors of the classical renin–angiotensin system (RAS) reduce tumor progression and are associated with better outcomes in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallejo Ardila, Dora Lucia, Walsh, Katrina A, Fifis, Theodora, Paolini, Rita, Kastrappis, Georgios, Christophi, Christopher, Perini, Marcos Vinicius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253054/
https://www.ncbi.nlm.nih.gov/pubmed/32448803
http://dx.doi.org/10.1136/jitc-2019-000487
_version_ 1783539269752586240
author Vallejo Ardila, Dora Lucia
Walsh, Katrina A
Fifis, Theodora
Paolini, Rita
Kastrappis, Georgios
Christophi, Christopher
Perini, Marcos Vinicius
author_facet Vallejo Ardila, Dora Lucia
Walsh, Katrina A
Fifis, Theodora
Paolini, Rita
Kastrappis, Georgios
Christophi, Christopher
Perini, Marcos Vinicius
author_sort Vallejo Ardila, Dora Lucia
collection PubMed
description BACKGROUND: It is now recognized that many anticancer treatments positively modulate the antitumor immune response. Clinical and experimental studies have shown that inhibitors of the classical renin–angiotensin system (RAS) reduce tumor progression and are associated with better outcomes in patients with colorectal cancer. RAS components are expressed by most immune cells and adult hematopoietic cells, thus are potential targets for modulating tumor-infiltrating immune cells and can provide a mechanism of tumor control by the renin–angiotensin system inhibitors (RASi). AIM: To investigate the effects of the RASi captopril on tumor T lymphocyte distribution in a mouse model of colorectal liver metastases. METHODS: Liver metastases were established in a mouse model using an autologous colorectal cancer cell line. RASi (captopril 750 mg/kg) or carrier (saline) was administered to the mice daily via intraperitoneal injection, from day 1 post-tumor induction to endpoint (day 15 or 21 post-tumor induction). At the endpoint, tumor growth was determined, and lymphocyte infiltration and composition in the tumor and liver tissues were analyzed by flow cytometry and immunohistochemistry (IHC). RESULTS: Captopril significantly decreased tumor viability and impaired metastatic growth. Analysis of infiltrating T cells into liver parenchyma and tumor tissues by IHC and flow cytometry showed that captopril significantly increased the infiltration of CD3(+) T cells into both tissues at day 15 following tumor induction. Phenotypical analysis of CD45(+) CD3(+) T cells indicated that the major contributing phenotype to this influx is a CD4 and CD8 double-negative T cell (DNT) subtype, while CD4(+) T cells decreased and CD8(+) T cells remained unchanged. Captopril treatment also increased the expression of checkpoint receptor PD-1 on CD8(+)and DNT subsets. CONCLUSION: Captopril treatment modulates the immune response by increasing the infiltration and altering the phenotypical composition of T lymphocytes and may be a contributing mechanism for tumor control.
format Online
Article
Text
id pubmed-7253054
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72530542020-06-05 Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases Vallejo Ardila, Dora Lucia Walsh, Katrina A Fifis, Theodora Paolini, Rita Kastrappis, Georgios Christophi, Christopher Perini, Marcos Vinicius J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: It is now recognized that many anticancer treatments positively modulate the antitumor immune response. Clinical and experimental studies have shown that inhibitors of the classical renin–angiotensin system (RAS) reduce tumor progression and are associated with better outcomes in patients with colorectal cancer. RAS components are expressed by most immune cells and adult hematopoietic cells, thus are potential targets for modulating tumor-infiltrating immune cells and can provide a mechanism of tumor control by the renin–angiotensin system inhibitors (RASi). AIM: To investigate the effects of the RASi captopril on tumor T lymphocyte distribution in a mouse model of colorectal liver metastases. METHODS: Liver metastases were established in a mouse model using an autologous colorectal cancer cell line. RASi (captopril 750 mg/kg) or carrier (saline) was administered to the mice daily via intraperitoneal injection, from day 1 post-tumor induction to endpoint (day 15 or 21 post-tumor induction). At the endpoint, tumor growth was determined, and lymphocyte infiltration and composition in the tumor and liver tissues were analyzed by flow cytometry and immunohistochemistry (IHC). RESULTS: Captopril significantly decreased tumor viability and impaired metastatic growth. Analysis of infiltrating T cells into liver parenchyma and tumor tissues by IHC and flow cytometry showed that captopril significantly increased the infiltration of CD3(+) T cells into both tissues at day 15 following tumor induction. Phenotypical analysis of CD45(+) CD3(+) T cells indicated that the major contributing phenotype to this influx is a CD4 and CD8 double-negative T cell (DNT) subtype, while CD4(+) T cells decreased and CD8(+) T cells remained unchanged. Captopril treatment also increased the expression of checkpoint receptor PD-1 on CD8(+)and DNT subsets. CONCLUSION: Captopril treatment modulates the immune response by increasing the infiltration and altering the phenotypical composition of T lymphocytes and may be a contributing mechanism for tumor control. BMJ Publishing Group 2020-05-24 /pmc/articles/PMC7253054/ /pubmed/32448803 http://dx.doi.org/10.1136/jitc-2019-000487 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical/Translational Cancer Immunotherapy
Vallejo Ardila, Dora Lucia
Walsh, Katrina A
Fifis, Theodora
Paolini, Rita
Kastrappis, Georgios
Christophi, Christopher
Perini, Marcos Vinicius
Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title_full Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title_fullStr Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title_full_unstemmed Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title_short Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
title_sort immunomodulatory effects of renin–angiotensin system inhibitors on t lymphocytes in mice with colorectal liver metastases
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253054/
https://www.ncbi.nlm.nih.gov/pubmed/32448803
http://dx.doi.org/10.1136/jitc-2019-000487
work_keys_str_mv AT vallejoardiladoralucia immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT walshkatrinaa immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT fifistheodora immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT paolinirita immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT kastrappisgeorgios immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT christophichristopher immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases
AT perinimarcosvinicius immunomodulatoryeffectsofreninangiotensinsysteminhibitorsontlymphocytesinmicewithcolorectallivermetastases